Hemosol falls while Northfield rises in blood substitute arena
This article was originally published in Clinica
Executive Summary
Last week saw contrasting fortunes for two blood substitute makers vying for a share of the as-yet-untapped US market. In what was a crushing blow for Hemosol, the firm saw its stock plunge after cancelling a key trial of its flagship product, Hemolink. Northfield Laboratories, on the other hand, watched its shares rise following an announcement that it had come to a special agreement with the US FDA for its product, PolyHeme.